Table 3

OXTR promoter CpG methylation status in peripheral blood mononuclear cells (PBMCs) and cortex samples of males

Site

AutD cases (95%CI), (n = 10)

Controls (95%CI), (n = 10)

t Test


PBMCs:

-860

41.0% (28.4 to 53.7)

13.8% (6.6 to 21.0)

0.0008

-901

48.1% (33.6 to 62.7)

36.9% (19.1 to 54.7)

0.3153

-924

71.1% (59.4 to 82.8)

59.3% (40.8 to 77.8)

0.2604

-934

58.7% (39.4 to 78.1)

19.8% (3.2 to 36.4)

0.0029

-959

48.6% (39.5 to 57.6)

41.7% (27.5 to 55.9)

0.3522

Cortex:

-860

38.8% (5.4 to 72.2)

14.9% (3.6 to 26.2)

0.1208

-901

47.1% (13.1 to 81.2)

13.3% (3.6 to 23.0)

0.0508

-924

64.3% (30.6 to 98.0)

26.6% (7.2 to 46.1)

0.0375

-934

61.0% (24.4 to 97.5)

19.4% (1.1 to 37.7)

0.0320

-959

20.5% (8.0 to 32.9)

19.4% (1.1 to 37.7)

0.9032


Bold text indicates a significant result by Satterthwaite test; %, percentage methylated. Cases and controls were all male.

CI = confidence interval; AutD = autism disorder.

Gregory et al. BMC Medicine 2009 7:62   doi:10.1186/1741-7015-7-62

Open Data